Therefore, while the biological plausibility of GLP-1 RAs as adjuncts in cancer therapy is strong, especially considering their impact on key molecular pathways such as PI3K/Akt, AMPK, and PKA, the next essential step involves translating these mechanistic insights into well-designed clinical trials. The gene discussed is GLP1R; the disease is cancer.